Press Releases
November 27th, 2018
JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema
August 23rd, 2018
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
June 21st, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients
May 16th, 2018
KalVista Pharmaceuticals Recognizes HAE Day
April 9th, 2018
HAEA comments on ICER HAE therapy assessment
February 25th, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
February 15th, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
January 24th, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
January 22nd, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
January 8th, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government
January 5th, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials
September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema
September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE
September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet
July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA
June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease
May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients
November 27th, 2018
JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema
August 23rd, 2018
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
June 21st, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients
May 16th, 2018
KalVista Pharmaceuticals Recognizes HAE Day
April 9th, 2018
HAEA comments on ICER HAE therapy assessment
February 25th, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
February 15th, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
January 24th, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
January 22nd, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
January 8th, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government
January 5th, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials
September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema
September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE
September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet
July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA
June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease
May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients
The US Hereditary Angioedema Association
10560 Main Street , Suite PS40
Fairfax City, VA 22030
Use of this site implies your agreement with our Terms of use / privacy policies
Copyright © 2019 US Hereditary Angioedema Association